Pα+: Day 1 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA Post published:February 14, 2024 Post category:Analysis/Pα+
Psychedelic Research Bulletin: January 2024 Post published:February 12, 2024 Post category:Psychedelics Research Review
The Interdisciplinary Annotated Psychedelic Research Bibliography of 2023 Post published:February 9, 2024 Post category:2023 Year in Review/Analysis
Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists Post published:February 8, 2024 Post category:Psychedelic Bulletin/Pα+
The Psychedelic Drug Development Pipeline: Bullseye Chart Year-End 2023 Post published:February 6, 2024 Post category:2023 Year in Review/Analysis
The Psychedelic News Feed: Jan 8 2024 – Feb 4, 2024 Post published:February 5, 2024 Post category:Psychedelic News Feed Archive
A Discussion with Ernesto Londoño, Author of “Trippy: The Peril and Promise of Medicinal Psychedelics” Post published:February 1, 2024 Post category:Interviews
Interview: Compass Pathways CEO Kabir Nath Discusses Commercialisation, ‘Psychological Support’ and Competitive Landscape Post published:January 31, 2024 Post category:Interviews/Pα+
Psychedelic Policy Reform & Legal Markets in 2023 Post published:January 30, 2024 Post category:2023 Year in Review/Analysis
Colorado Department of Revenue Natural Medicine Division Listening Sessions: Round 2 Post published:January 30, 2024 Post category:Colorado Natural Medicine Advisory Bulletin